TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...

Full description

Bibliographic Details
Main Authors: Sander AL Palit, Daniel Vis, Suzan Stelloo, Cor Lieftink, Stefan Prekovic, Elise Bekers, Ingrid Hofland, Tonći Šuštić, Liesanne Wolters, Roderick Beijersbergen, Andries M Bergman, Balázs Győrffy, Lodewyk FA Wessels, Wilbert Zwart, Michiel S van der Heijden
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2019-12-01
Series:eLife
Subjects:
prostate cancer
therapy resistance
androgen receptor
TLE3
glucocorticoid receptor
Enzalutamide
Online Access:https://elifesciences.org/articles/47430

Similar Items

Similar Items